|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
8 994 | 5 881 | 5 354 | 6 869 | 6 869 | - |
| Entreprise Value (EV)1 |
8 994 | 5 188 | 4 502 | 5 375 | 5 111 | 4 600 |
| P/E ratio |
62,0x | 8,90x | 17,3x | 75,9x | 51,9x | 21,0x |
| Yield |
- | - | - | - | - | - |
| Capitalization / Revenue |
19,9x | 6,89x | 5,53x | 6,95x | 5,69x | 4,32x |
| EV / Revenue |
19,9x | 6,08x | 4,65x | 5,44x | 4,23x | 2,90x |
| EV / EBITDA |
53,8x | 11,7x | 11,9x | 46,1x | 38,4x | 16,5x |
| Price to Book |
- | 4,58x | 3,19x | 3,58x | 3,26x | 2,73x |
| Nbr of stocks (in thousands) |
295 853 | 298 983 | 303 846 | 310 244 | 310 244 | - |
| Reference price (USD) |
30,4 | 19,7 | 17,6 | 22,1 | 22,1 | 22,1 |
| Last update |
02/26/2018 | 02/12/2019 | 02/25/2020 | 01/11/2021 | 01/11/2021 | 01/11/2021 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
452 | 854 | 968 | 988 | 1 207 | 1 588 |
| EBITDA1 |
167 | 444 | 378 | 117 | 133 | 279 |
| Operating profit (EBIT)1 |
166 | 439 | 369 | 108 | 158 | 406 |
| Operating Margin |
36,7% | 51,4% | 38,2% | 10,9% | 13,1% | 25,6% |
| Pre-Tax Profit (EBT)1 |
159 | 452 | 398 | 121 | 179 | 441 |
| Net income1 |
154 | 690 | 321 | 99,7 | 142 | 348 |
| Net margin |
34,1% | 80,8% | 33,2% | 10,1% | 11,8% | 21,9% |
| EPS2 |
0,49 | 2,21 | 1,02 | 0,29 | 0,43 | 1,05 |
| Dividend per Share2 |
- | - | - | - | - | - |
| Last update |
02/26/2018 | 02/12/2019 | 02/25/2020 | 11/06/2020 | 11/06/2020 | 01/11/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
- | - | - | - | - | - |
| Net Cash position1 |
- | 693 | 852 | 1 494 | 1 758 | 2 269 |
| Leverage (Debt / EBITDA) |
- | -1,56x | -2,26x | -12,8x | -13,2x | -8,12x |
| Free Cash Flow1 |
144 | 382 | 514 | 47,2 | 265 | 365 |
| ROE (Net Profit / Equities) |
54,1% | 87,8% | 21,6% | 10,9% | 7,66% | 16,4% |
| Shareholders' equity1 |
285 | 786 | 1 487 | 916 | 1 855 | 2 120 |
| ROA (Net Profit / Asset) |
23,5% | 66,4% | 19,4% | - | - | - |
| Assets1 |
655 | 1 039 | 1 654 | - | - | - |
| Book Value Per Share2 |
- | 4,29 | 5,53 | 6,19 | 6,79 | 8,11 |
| Cash Flow per Share2 |
0,53 | 1,33 | 1,67 | 0,83 | 0,50 | - |
| Capex1 |
21,1 | 33,3 | 12,8 | 23,3 | 29,1 | 36,9 |
| Capex / Sales |
4,67% | 3,90% | 1,33% | 2,36% | 2,41% | 2,32% |
| Last update |
02/26/2018 | 02/12/2019 | 02/25/2020 | 01/22/2021 | 01/22/2021 | 01/22/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
EXELIXIS, INC.
The most promising biotech firm in the US? |
Capitalization (USD) 6 868 801 296 Net sales (USD) 967 775 000 Sales / Employee (USD) 1 568 517 Free-Float capitalization (USD) 6 731 422 029 Avg. Exchange 20 sessions (USD) 61 774 747 Average Daily Capital Traded 0,90%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
